Document Detail


Propafenon, a new anti-arrhythmic drug (author's transl)
MedLine Citation:
PMID:  60209     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Propafenon, at an initial oral dose of 900 mg, proved an effective anti-arrhythmic drug in 34 patients with frequent ventricular and(or) supraventricular extrasystoles at rest. Long-term ECG monitoring of seven patients revealed that this effect lasted about eight hours. It can be maintained by an oral dose of 300 mg propafenon at eight-hourly intervals, as demonstrated in 21 further patients. Rapid anti-arrhythmic action was achieved in six acute cases with 1.0-1.5 mg propafenon per kg body weight by quick infusion, and lasted for one to one-and-a-half hours. In such cases the drug should, therefore, be given synchronously by the oral route. Side effects related to the gastrointestinal tract, sinus automatism as well as atrio-ventricular and intraventricular conduction, but in no case were very serious.
Authors:
E Aldor; H Heeger
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; English Abstract; Journal Article    
Journal Detail:
Title:  Deutsche medizinische Wochenschrift (1946)     Volume:  101     ISSN:  0012-0472     ISO Abbreviation:  Dtsch. Med. Wochenschr.     Publication Date:  1976 Sep 
Date Detail:
Created Date:  1976-10-29     Completed Date:  1976-10-29     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0006723     Medline TA:  Dtsch Med Wochenschr     Country:  GERMANY, WEST    
Other Details:
Languages:  ger     Pagination:  1318-22     Citation Subset:  IM    
Vernacular Title:
Propafenon--ein neues Antiarrhythmikum
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Anti-Arrhythmia Agents / administration & dosage,  adverse effects,  therapeutic use*
Cardiac Complexes, Premature / drug therapy*,  physiopathology
Chemical Phenomena
Chemistry
Humans
Injections, Intravenous
Long-Term Care
Propiophenones / administration & dosage,  adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Propiophenones

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Negative silver staining in A-T and satellite DNA-rich regions of human chromosomes.
Next Document:  Visible and non-visible EEG changes demonstrated by spectral parameter analysis.